Doxorubicin
- PDF / 169,382 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 3 Downloads / 181 Views
1 S
Reduced left ventricular ejection fraction: 4 case reports In a study of patients treated at Vancouver General Hospital, Canada, four women including an elderly woman [exact ages at time of ADR onsets not stated] were described, who developed cardiotoxicity presenting as reduced left ventricular ejection fraction during treatment with doxorubicin for breast cancer or sarcoma [dosages, routes, times to reactions onsets and outcomes not stated]. All four women with breast cancer (3 patients) and sarcoma (1 patient), underwent treatment with doxorubicin at the age of 47–68 years. The patients were treated with doxorubicin at a cumulative doses of 300–450 mg/m2. Subsequently, all women developed doxorubicin-induced cardiotoxicity, presenting as reduced left ventricular ejection fraction by 20-36%. The women additionally showed a WT/S427L or WT/WT RARG variant, which increased susceptibility of cardiotoxicity secondary to doxorubicin. Christidi E, et al. Variation in RARG increases susceptibility to doxorubicin-induced cardiotoxicity in patient specific induced pluripotent stem cell-derived cardiomyocytes. 803505398 Scientific Reports 10: No. 1, 25 Jun 2020. Available from: URL: http://doi.org/10.1038/s41598-020-65979-x
0114-9954/20/1825-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 10 Oct 2020 No. 1825
Data Loading...
